5:28 PM
 | 
Jan 28, 2013
 |  BC Extra  |  Company News

FDA reviewers question Bronchitol efficacy

FDA reviewers said efficacy results for Bronchitol mannitol from Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY) are "inconsistent," as the product met the primary endpoint in only one of two Phase III trials to manage cystic fibrosis (CF). Specifically, the reviewers concluded Bronchitol significantly improved the proportion of patients with...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >